Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
In summary, our study demonstrated that TXNDC12 could activate β-catenin via protein-protein interaction and promote ZEB1-mediated EMT and HCC metastasis.
|
31570854 |
2020 |
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Collectively, our data suggested that miR-623 suppressed the progression of HCC by regulating the PI3K/Akt, Wnt/β-catenin, and ERK/JNK pathways by targeting XRCC5 in HCC in vitro, indicating that miR-623 may be a target for the therapy of HCC.
|
31190447 |
2020 |
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Co-activation of both Wnt/β-catenin and Akt/mTOR pathways was found in 14.4% of our HCC patient cohort.
|
31541681 |
2020 |
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, while overexpression of CASC2c decreased β-catenin expression in HCC and GC cells, it increased that in CRC cells.
|
31625123 |
2020 |
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Therefore, our study reveals the evolving nature of β-catenin in HCC to establish it as a compound tumor promoter during the progression of the disease.
|
31015417 |
2019 |
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
The expression levels of CTNNB1 and MMP9 decreased by knocked down XRCC5 which may promote the progression of HCC via the Wnt/β-catenin signaling pathway.
|
31599408 |
2019 |
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
PRRl1 mRNA expression was found positively correlated with β-catenin (R = 0.5472, P ˂ 0.0001), c-myc (R = 0.5527, P ˂ 0.0001) and cyclinD1 (R = 0.3948, P = 0.0003) in HCC tissues.
|
30248355 |
2019 |
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Some driver genes are significantly linked to HCC gender (<i>CTNNB1, ALB, TP53</i>, and <i>AXIN1</i>), race (<i>TP53</i> and <i>CDKN2A</i>), and age (<i>RB1</i>) disparities.
|
30242023 |
2019 |
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Clinicopathological parameters, progression-free survival (PFS) and overall survival (OS) were evaluated to analyze the association of β-catenin expression with prognosis for HCC patients after TACE.
|
30842141 |
2019 |
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
By screening β-catenin-interacting proteins, we found that Nek2 could bind β-catenin in sorafenib-treated HCC cell lines.
|
31319849 |
2019 |
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
We studied mice with activation of β-catenin in liver (Apc<sup>ko-liv</sup> mice) and male C57Bl/6 mice given injections of diethylnitrosamine, which each develop HCCs.
|
31194980 |
2019 |
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Finally, Western blot results indicated that silencing FBXO17 might function through downregulating the expression of proteins in wnt/β-catenin pathway such as c-Myc, MMP-9, and MMP-2 while upregulating GSK-3β level, thereby promoting the malignant progression of HCC.
|
31646557 |
2019 |
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
A β‑catenin mutant and β‑catenin wild‑type HCC models were treated once daily with i) 10 mg/kg sorafenib, ii) 15 mg/kg refametinib (or 25 mg/kg selumetinib), or iii) sorafenib/refametinib.
|
30747223 |
2019 |
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
UNC119 promotes the growth and migration of hepatocellular carcinoma via Wnt/β-catenin and TGF-β/EMT signaling pathways.
|
29552781 |
2019 |
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
CTNNB1 mutations were similarly observed in K19<sup>+</sup> and K19<sup>-</sup> HCC (23% and 19%, respectively), but rare in S-iCCA (3%).
|
31017316 |
2019 |
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Taken together, our results suggest that PAB exerts anti-cancer activity in HCC cells through inhibition of STAT3, ERK1/2, Akt, and GSK-3β/β-catenin carcinogenic signaling pathways, and may be used as a phytomedicine in the treatment of HCC.
|
31004883 |
2019 |
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
In addition, immunohistochemistry (IHC) revealed that the amount of nuclear-localized β-catenin was significantly higher in KC/TFF1<sup>-/-</sup> mice than in KC mice and that human HCC tissue showed contradictory expression patterns for β-catenin and TFF1, confirming the in vitro observations.
|
31733149 |
2019 |
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
ODC1 promotes proliferation and mobility via the AKT/GSK3β/β-catenin pathway and modulation of acidotic microenvironment in human hepatocellular carcinoma.
|
31239700 |
2019 |
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Further in vivo experiments suggested that PRMT5 and β-catenin played a pivotal role in MTDH-mediated HCC metastasis.
|
31498866 |
2019 |
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
E-cadherin signaling plays an important role in hepatocellular carcinoma (HCC) initiation and progression considering the highly mutated frequency of CTNNB1 (27%).
|
31802937 |
2019 |
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
In this study, we found that 34.8% of human HCC samples with FAK amplification also show β-catenin mutations, suggesting a co-occurrence of FAK overexpression and β-catenin mutations in HCC.
|
31069844 |
2019 |
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Overexpressed FZD4 eventually activated Wnt/β-catenin pathway and contributed to HCC progression.
|
31807066 |
2019 |
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
In hepatocellular carcinoma (HCC), Wnt/CTNNB1 mutations characterize the immune-excluded class (cold tumors) and might represent the biomarkers predicting resistance to immune checkpoint inhibitors.
|
30617138 |
2019 |
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Loss- and gain-of-function assays further confirmed that β-catenin is essential for HEG1-mediated promotion of HCC invasion, metastasis and EMT.
|
31278131 |
2019 |
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
We previously identified several genes that are regulated on the overexpression of β-catenin in the HCC cell line that are suggested to be novel Wnt/β-catenin targets playing effective roles in cancer.
|
30541713 |
2019 |